

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected new or serious adverse reactions. See the “Undesirable effects” section for advice on the reporting of adverse reactions.

Veklury is temporarily authorised – see "Properties/Effects" section.

### **Veklury®**

#### **Composition**

*Veklury 100 mg powder for concentrate for solution for infusion*

##### *Active substances*

Remdesivir

##### *Excipients*

Betadex sulfobutyl ether sodium, hydrochloric acid (to adjust pH), sodium hydroxide (to adjust pH).

A 100 mg Veklury dose of powder for concentrate for solution for infusion contains approximately 211.8 mg sodium and 3 g betadex sulfobutyl ether sodium.

#### **Pharmaceutical form and active substance quantity per unit**

Powder for concentrate for solution for infusion (powder for concentrate).

White to off-white to yellow powder.

Each vial contains 100 mg of remdesivir. After reconstitution, each vial contains 5 mg/ml of remdesivir solution.

#### **Indications/Uses**

Veklury is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults

- with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment),
- who do not require supplemental oxygen or hospitalisation for COVID-19 and who are at risk of developing a severe COVID-19 course

(see “Properties/Effects”).

### **Dosage/Administration**

Veklury should be used under conditions where treatment of severe hypersensitivity reactions, including anaphylaxis, is possible. Patients should be monitored when receiving Veklury (see section “Warnings and precautions”).

Treatment should be initiated as soon as possible after a positive viral test for SARS-CoV-2 (see “Properties/Effects”).

The recommended dosage of Veklury in adults is:

- Day 1 – single loading dose of remdesivir 200 mg given by intravenous infusion over 30 to 120 minutes
- Day 2 onwards – remdesivir 100 mg given once daily by intravenous infusion over 30 to 120 minutes.

#### *Duration of treatment*

For patients with pneumonia requiring supplemental oxygen, the total duration of treatment should be at least 5 days and not more than 10 days.

For patients who do not require supplemental oxygen or hospitalization for COVID-19 and who are at risk of developing a severe COVID-19 course, the total duration of treatment should be 3 days.

#### *Special dosage instructions*

##### *Patients with impaired hepatic function*

The pharmacokinetics of Veklury have not been evaluated in patients with hepatic impairment. It is not known if dosage adjustment is appropriate in patients with hepatic impairment (see “Warnings and precautions” and “Pharmacokinetics”).

##### *Patients with impaired renal function*

The pharmacokinetics of Veklury have not been evaluated in patients with renal impairment. Patients with an estimated glomerular filtration rate (eGFR)  $\geq 30$  ml/min have received remdesivir for treatment of COVID-19 with no dose adjustment. Veklury should not be used in patients with eGFR  $< 30$  ml/min (see “Warnings and precautions” and “Pharmacokinetics”).

##### *Elderly patients*

No dose adjustment of Veklury is required in patients over the age of 65 years (see “Properties/Effect” and “Pharmacokinetics”).

##### *Paediatric patients*

The safety and efficacy of Veklury in children under the age of 18 years have not yet been established. There is insufficient data available.

### *Mode of administration*

For intravenous infusion use.

Veklury is for administration by intravenous infusion after reconstitution and further dilution.

It must not be given as an intramuscular (IM) injection.

For instructions on reconstitution and dilution of the medicinal product before administration, see “Instructions for handling”.

**Table 1: Recommended rate of infusion for reconstituted and diluted Veklury powder for concentrate for solution for infusion**

<b>Infusion Bag Volume</b>	<b>Infusion Time</b>	<b>Rate of Infusion</b>
250 ml	30 min	8.33 ml/min
	60 min	4.17 ml/min
	120 min	2.08 ml/min
100 ml	30 min	3.33 ml/min
	60 min	1.67 ml/min
	120 min	0.83 ml/min

### **Contraindications**

Hypersensitivity to the active substance or to any of the excipients.

### **Warnings and precautions**

#### *Hypersensitivity including infusion-related and anaphylactic reactions*

Hypersensitivity reactions including infusion-related and anaphylactic reactions have been observed during and following administration of Veklury. Signs and symptoms may include hypotension, hypertension, tachycardia, bradycardia, hypoxia, fever, dyspnoea, wheezing, angioedema, rash, nausea, vomiting, diaphoresis, and shivering. Slower infusion rates, with a maximum infusion time of up to 120 minutes, can be considered to potentially prevent these signs and symptoms. Monitor patients for hypersensitivity reactions during and following administration of Veklury as clinically appropriate. If signs and symptoms of a clinically significant hypersensitivity reaction occur, immediately discontinue administration of Veklury and initiate appropriate treatment.

#### *Transaminase elevations*

Transaminase elevations have been observed in the Veklury clinical studies, including in healthy volunteers and patients with COVID-19. Liver function should be determined in all patients prior to starting Veklury and should be monitored while receiving it as clinically appropriate. No clinical studies with Veklury have been conducted in patients with hepatic impairment. Veklury should only be used in patients with hepatic impairment if the potential benefit outweighs the potential risk.

- Veklury should not be initiated in patients with alanine aminotransferase (ALT)  $\geq 5$  times the upper limit of normal (ULN) at baseline
  - Veklury should be discontinued in patients who develop:
    - ALT  $\geq 5$  times the ULN during treatment with Veklury. It may be restarted when ALT is  $< 5$  times the ULN.
- OR
- ALT elevation accompanied by signs or symptoms of liver inflammation or increasing conjugated bilirubin, alkaline phosphatase, or international normalised ratio (INR) (see “Undesirable effects” and “Pharmacokinetics”).

### *Renal Impairment*

In animal studies on rats and monkeys, severe renal toxicity was observed (see “Preclinical data”). The mechanism of this renal toxicity is not fully understood. A relevance for humans cannot be excluded.

All patients should have eGFR determined prior to starting Veklury and while receiving it as clinically appropriate. Veklury should not be used in patients with eGFR  $< 30$  ml/min.

### *Risk of reduced antiviral activity when co-administered with chloroquine or hydroxychloroquine*

Co-administration of Veklury and chloroquine phosphate or hydroxychloroquine sulphate is not recommended based on cell culture data demonstrating an antagonistic effect of chloroquine on the intracellular metabolic activation and antiviral activity of remdesivir (see section “Interactions” and “Properties/Effects”).

### *Excipients*

Veklury contains betadex sulfobutyl ether sodium, which is renally cleared and accumulates in patients with decreased renal function, which may potentially adversely affect renal function. Veklury should not be used in patients with eGFR  $< 30$  ml/min (see “Dosage/Administration” and “Pharmacokinetics”).

A 100 mg Veklury dose of powder for concentrate for solution for infusion contains approximately 211.8 mg sodium, equivalent to 10.6% of the WHO recommended maximum daily dietary intake of 2 g sodium for an adult.

### **Interactions**

No clinical interaction studies have been performed with Veklury. The overall potential for interactions is currently unknown; patients should remain under close observation during the days of Veklury administration. Due to potential antagonism observed in cell culture, concomitant use of Veklury with chloroquine phosphate or hydroxychloroquine sulphate is not recommended.

### *Effect of Veklury on other medicinal products*

*In vitro*, remdesivir is an inhibitor of CYP3A4. At physiologically relevant concentrations, remdesivir or its metabolites GS-441524 and GS-704277 did not inhibit CYP1A2, 2B6, 2C8, 2C9, 2C19, and 2D6 *in vitro*. Remdesivir may however transiently inhibit CYP2B6, 2C8, 2C9 and 2D6 on the first day of administration. The clinical relevance of this inhibition was not studied. The potential for time-dependent inhibition of CYP450 enzymes by remdesivir was not studied.

Remdesivir inhibited OAT3, OCT1, MATE-1, OATP1B1 and OATP1B3 *in vitro*. No inhibition potential predicted for OAT1 and OCT2.

Remdesivir may transiently increase plasma concentrations of medicinal products that are substrates of CYP3A or OATP 1B1/1B3. No data is available, however it can be suggested that medicinal products that are substrates of CYP3A4 or substrates of OATP 1B1/1B3 should be administered at least 2 hours after remdesivir. Remdesivir induced CYP1A2 and potentially CYP3A *in vitro*, but not CYP2B6 *in vitro*. Co-administration of Veklury with CYP1A2 or CYP3A4 substrates with narrow therapeutic index may lead to loss of their efficacy.

*In vitro* data indicates no clinically relevant inhibition of UGT, 1A3, 1A4, 1A6, 1A9 or 2B7 by remdesivir or its metabolites GS-441524 and GS-704277.

At physiologically relevant concentrations, remdesivir and its metabolites did not inhibit P-gp and BCRP *in vitro*.

Dexamethasone is a substrate of CYP3A4 and although remdesivir inhibits CYP3A4, due to remdesivir's rapid clearance after intravenous administration, remdesivir is unlikely to have a significant effect on dexamethasone exposure.

### *Effect of other medicinal products on Veklury*

*In vitro*, remdesivir is a substrate for esterases in plasma and tissue, drug metabolising enzyme CYP3A4, and is a substrate for Organic Anion Transporting Polypeptides 1B1 (OATP1B1) and P-glycoprotein (P-gp) transporters.

The potential of interaction of Veklury with inhibitors/inducers of the hydrolytic pathway (esterase) or CYP3A4 has not been studied. The risk of clinically relevant interaction is unknown. Strong inhibitors may result in increased remdesivir exposure. The use of strong inducers (e.g. rifampicin) may decrease plasma concentrations of remdesivir and is not recommended.

Dexamethasone is reported to be a moderate inducer of CYP3A and P-gp. Induction is dose-dependent and occurs after multiple doses. Dexamethasone is unlikely to have a clinically significant effect on Veklury as Veklury has a moderate-high hepatic extraction ratio, and is used for a short duration in the treatment of COVID-19.

### **Pregnancy, lactation**

Women of child-bearing potential have to use effective contraception during treatment.

#### *Pregnancy*

There are no data from the use of Veklury in pregnant women. Animal studies are insufficient with respect to reproductive toxicity (see “Preclinical Data”). Veklury should not be used during pregnancy unless the clinical condition of the women requires treatment with it.

#### *Lactation*

It is unknown whether remdesivir is excreted in human milk or the effects on the breast-fed infant, or the effects on milk production.

Because of the potential for viral transmission to SARS-CoV-2 negative infants and adverse reactions from the drug in breast-feeding infants, a decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Veklury therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

#### *Fertility*

No human data on the effect of Veklury on fertility are available. In male rats, there was no effect on mating or fertility with Veklury treatment. In female rats, however, an impairment of fertility was observed (see “Preclinical data”). The relevance for humans is unknown.

### **Effects on ability to drive and use machines**

No corresponding studies have been performed.

### **Undesirable effects**

#### *Summary of the safety profile*

The safety profile of Veklury is based on data from 4 Phase 1 studies in healthy adults, 3 Phase 3 studies in hospitalised patients with COVID-19, 1 Phase 3 study in non-hospitalised patients with COVID-19, from hospitalised patients with COVID-19 who received Veklury in a compassionate use program and from post-marketing experience. The most common adverse reaction in healthy volunteers is increased transaminases (14%). The most common adverse reaction in patients with COVID-19 is nausea (4%).

*Tabulated summary of adverse reactions*

The adverse reactions in Table 2 are listed below by system organ class and frequency. Frequencies are defined as follows: Very common ( $\geq 1/10$ ), common ( $\geq 1/100$  to  $< 1/10$ ), uncommon ( $\geq 1/1000$  to  $< 1/100$ ), rare ( $\geq 1/10,000$  to  $< 1/1000$ ), not known (frequency cannot be estimated from the available data).

**Table 2: Tabulated list of adverse reactions**

Frequency	Adverse reaction
<i>Immune system disorders</i>	
Rare	hypersensitivity
Not known	anaphylactic reaction <sup>1</sup>
<i>Nervous system disorders</i>	
Common	headache
<i>Cardiac disorders</i>	
Not known	sinus bradycardia <sup>2</sup>
<i>Gastrointestinal disorders</i>	
Common	nausea
<i>Hepatobiliary disorders</i>	
Very common	transaminases increased (14%)
<i>Skin and subcutaneous tissue disorders</i>	
Common	rash
<i>Investigations</i>	
Very common	prothrombin time prolonged (44%)
<i>Injury, poisoning and procedural complications</i>	
Rare	infusion-related reaction

<sup>1</sup> Adverse reaction identified through post-marketing surveillance.

<sup>2</sup> Reported in post-marketing, usually normalised within 4 days following last Veklury administration without additional intervention.

*Description of selected undesirable effects*

*Transaminases Increased*

In healthy volunteer studies, increases in ALT, aspartate aminotransferase (AST) or both in subjects who received Veklury were grade 1 (10%) or grade 2 (4%). In a randomised, double-blind, placebo-controlled clinical study of patients with COVID-19 (NIAID ACTT-1), any grade ( $\geq 1.25 \times$  upper limit of normal (ULN)) laboratory abnormalities of increased AST and increased ALT occurred in 33% and 32% of patients, respectively, receiving Veklury compared with 44% and 43% of patients, respectively, receiving placebo. Grade  $\geq 3$  ( $\geq 5.0 \times$  ULN) laboratory abnormalities of increased AST and increased ALT occurred in 6% and 3% of patients, respectively, receiving Veklury compared with 8% and 6% of patients, respectively, receiving placebo. In a randomised, open-label multi-centre clinical study (Study GS-US-540-5773) in hospitalised patients with severe COVID-19 receiving Veklury for 5 (n=200) or 10 days (n=197), any grade laboratory abnormalities of increased AST and increased ALT occurred in 40% and 42% of patients, respectively, receiving Veklury. Grade  $\geq 3$  laboratory abnormalities of increased AST and increased ALT both occurred in 7% of patients

receiving Veklury. In a randomised, open-label multi-centre clinical study (Study GS-US-540-5774) in hospitalised patients with moderate COVID-19 receiving Veklury for 5 (n=191) or 10 days (n=193) compared to standard of care (n=200), any grade laboratory abnormalities of increased AST and increased ALT occurred in 32% and 33% of patients, respectively, receiving Veklury, and 33% and 39% of patients, respectively, receiving standard of care. Grade  $\geq 3$  laboratory abnormalities of increased AST and increased ALT occurred in 2% and 3% of patients, respectively, receiving Veklury and 6% and 8%, respectively, receiving standard of care.

### *Prothrombin time increased*

In a clinical study (NIAID ACTT-1) of patients with COVID-19, the incidence of increased prothrombin time or INR (predominantly Grades 1-2) was higher in subjects who received Veklury compared to placebo, with no difference observed in the incidence of bleeding events between the two groups. Prothrombin time should be monitored while receiving Veklury as clinically appropriate. In Study GS-US-540-9012, the incidence of increased prothrombin time or INR was similar in patients treated with Veklury compared to placebo.

### *Reporting of suspected undesirable effects*

Reporting suspected adverse reactions after authorisation of the medicinal product is very important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions online via the EIViS portal (Electronic Vigilance System). You can obtain information about this at [www.swissmedic.ch](http://www.swissmedic.ch).

## **Overdose**

Treatment of overdose with Veklury should consist of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. There is no specific antidote for overdose with remdesivir.

## **Properties/Effects**

*ATC code*

J05AB16

### *Mechanism of action*

Remdesivir is an adenosine nucleotide prodrug that is metabolised within host cells to form the pharmacologically active nucleoside triphosphate metabolite. Remdesivir triphosphate acts as an analog of adenosine triphosphate (ATP) and competes with the natural ATP substrate for incorporation into nascent RNA chains by the SARS-CoV-2 RNA-dependent RNA polymerase, which results in delayed chain termination during replication of the viral RNA. As an additional mechanism, remdesivir triphosphate can also inhibit viral RNA synthesis following its incorporation into the template viral RNA as a result of read-through by the viral polymerase that may occur in the presence



of higher nucleotide concentrations. When remdesivir nucleotide is present in the viral RNA template, the efficiency of incorporation of the complementary natural nucleotide is compromised, thereby inhibiting viral RNA synthesis.

### *Pharmacodynamics*

#### *Antiviral Activity*

Remdesivir exhibited *in vitro* activity against a clinical isolate of SARS-CoV-2 in primary human airway epithelial cells with a 50% effective concentration (EC<sub>50</sub>) of 9.9 nM after 48 hours of treatment. Remdesivir inhibited the replication of SARS-CoV-2 in the continuous human lung epithelial cell line Calu-3 with an EC<sub>50</sub> value of 280 nM after 72 hours of treatment. The EC<sub>50</sub> values of remdesivir against SARS-CoV-2 in Vero cells were 137 nM at 24 hours and 750 nM at 48 hours post-treatment. The antiviral activity of remdesivir was antagonised by chloroquine phosphate in a dose-dependent manner when the two drugs were co-incubated at clinically relevant concentrations in HEP-2 cells infected with respiratory syncytial virus (RSV). Higher remdesivir EC<sub>50</sub> values were observed with increasing concentrations of chloroquine phosphate. Increasing concentrations of chloroquine phosphate reduced formation of remdesivir triphosphate in normal human bronchial epithelial cells.

#### *Resistance*

Cell culture resistance profiling of remdesivir using the rodent CoV murine hepatitis virus identified 2 substitutions (F476L and V553L) in the viral RNA-dependent RNA polymerase at residues conserved across CoVs that conferred 5.6-fold reduced susceptibility to remdesivir. Introduction of the corresponding substitutions (F480L and V557L) into SARS-CoV resulted in 6-fold reduced susceptibility to remdesivir cell culture and attenuated SARS-CoV pathogenesis in a mouse model.

The cell culture development of SARS-CoV-2 resistance to remdesivir has not been assessed to date. No clinical data are available on the development of SARS-CoV-2 resistance to remdesivir.

#### *Clinical efficacy*

##### *Clinical Studies in Subjects with COVID-19*

###### *NIAID ACTT-1 Study (CO-US-540-5776)*

A randomised, double-blind, placebo-controlled clinical study evaluated Veklury 200 mg once daily for 1 day followed by Veklury 100 mg once daily for up to 9 days (for a total of up to 10 days of intravenously administered therapy) in hospitalised adult patients with COVID-19 with evidence of lower respiratory tract involvement. The study enrolled 1062 hospitalised patients: 105 (9.9%) patients with mild/moderate disease (10% in both treatment groups) and 957 (90.1%) patients with severe disease (90% in both treatment groups). Mild/moderate disease was defined as SpO<sub>2</sub> > 94% and respiratory rate < 24 breaths/minute without supplemental oxygen; severe disease was defined as an SpO<sub>2</sub> ≤ 94% on room air, a respiratory rate ≥ 24 breaths/min, an oxygen requirement, or a

requirement for mechanical ventilation. A total of 285 patients (26.8%) (n=131 received Veklury) were on mechanical ventilation/Extracorporeal Membrane Oxygenation (ECMO). Patients were randomised 1:1, stratified by disease severity at enrolment, to receive Veklury (n=541) or placebo (n=521), plus standard of care.

The baseline mean age was 59 years and 36% of patients were aged 65 or older. Sixty-four percent were male, 53% were White, 21% were Black, 13% were Asian. The most common comorbidities were hypertension (51%), obesity (45%), type 2 diabetes mellitus (31%); the distribution of comorbidities was similar between the two treatment groups.

Approximately 38.4% (208/541) of the patients received a 10-day treatment course with Veklury.

The primary clinical endpoint was time to recovery within 29 days after randomisation, defined as either discharged from hospital (with or without limitations of activity and with or without home oxygen requirements) or hospitalised but not requiring supplemental oxygen and no longer requiring ongoing medical care. The median time to recovery was 10 days in the Veklury group compared to 15 days in the placebo group (recovery rate ratio 1.29; [95% CI 1.12 to 1.49],  $p < 0.001$ ).

The outcome differed relevantly between the two strata. In the severe disease stratum time to recovery was 11 days in the Veklury group and 18 days in the placebo group (recovery rate ratio 1.31 [95% CI 1.12 to 1.52]). For the mild/moderate disease stratum, time to recovery was not different between the two groups (5 days for both, remdesivir and placebo).

The clinical benefit of Veklury was most apparent in patients receiving oxygen, however, not on high-flow oxygen or ventilation, at Day 1 (recovery rate ratio 1.45 [95% CI 1.18 to 1.79]). For patients who were receiving mechanical ventilation or ECMO on Day 1, no difference in recovery rate was observed between the treatment groups (0.98 [95% CI 0.70 to 1.36]).

Overall, 29-day mortality was 11.6% for the Veklury group vs 15.4% for the placebo group (hazard ratio, 0.73; [95% CI 0.52 to 1.03];  $p=0.07$ ).

### *Study GS-US-540-5773 in patients with severe COVID-19*

A randomised, open-label multi-centre clinical study (GS-US-540-5773) of patients at least 12 years of age with confirmed SARS-CoV-2 infection, oxygen saturation  $\leq 94\%$  on room air, and radiological evidence of pneumonia compared 200 patients who received Veklury for 5 days with 197 patients who received Veklury for 10 days. Patients on mechanical ventilation at screening were excluded. All patients received 200 mg of Veklury on Day 1 and 100 mg once daily on subsequent days, plus standard of care. The primary endpoint was clinical status on Day 14 assessed on a 7-point ordinal scale ranging from hospital discharge to increasing levels of oxygen and ventilatory support to death.

At baseline, the median age of patients was 61 years (range, 20 to 98 years); 64% were male, 75% were White, 12% were Black, and 12% were Asian. More patients in the 10-day group than the 5-day group required invasive mechanical ventilation or ECMO (5% vs 2%), or high-flow oxygen support (30% vs 25%), at baseline. Median duration of symptoms and hospitalization prior to first dose of Veklury were similar across treatment groups.

Overall, after adjusting for between-group differences at baseline, patients receiving a 5-day course of Veklury had similar clinical status at Day 14 as those receiving a 10-day course (odds ratio for improvement: 0.75; [95% CI 0.51 to 1.12]). In addition, there were no statistically significant differences in recovery rates or mortality rates in the 5-day and 10-day groups once adjusted for between group differences at baseline. All-cause 28-day mortality was 12% vs 14% in the 5- and 10-day treatment groups, respectively.

### *Study GS-US-540-5774 in patients with moderate COVID-19*

A randomized, open-label multi-centre clinical study (GS-US-540-5774) of hospitalised patients at least 12 years of age with confirmed SARS-CoV-2 infection and radiological evidence of pneumonia without reduced oxygen levels compared treatment with Veklury for 5 days (n=191) and treatment with Veklury for 10 days (n=193) with standard of care (n=200). Patients treated with Veklury received 200 mg on Day 1 and 100 mg once daily on subsequent days. The primary endpoint was clinical status on Day 11 assessed on a 7-point ordinal scale ranging from hospital discharge to increasing levels of oxygen and ventilatory support to death.

At baseline, the median age of patients was 57 years (range, 12 to 95 years); 61% were male, 61% were White, 19% were Black, and 19% were Asian. Baseline clinical status, oxygen support status, and median duration of symptoms and hospitalization prior to first dose of Veklury were similar across treatment groups.

Overall, the odds of improvement in the ordinal scale were higher in the 5-day Veklury group at Day 11 when compared to those receiving only standard of care (odds ratio, 1.65; [95% CI, 1.09 to 2.48], p=0.017). The odds of improvement in clinical status with the 10-day treatment group when compared to those receiving only standard of care were not statistically significant (odds ratio 1.31; [95% CI 0.88 to 1.95]). All-cause 28-day mortality for the 5-day, 10-day, and standard of care groups was 1%, 1.6%, and 2%, respectively.

### *Study GS-US-540-9012 in patients with confirmed COVID-19 at high risk for disease progression*

A randomized, double-blind, placebo-controlled, clinical trial (GS-US-540-9012) evaluated Veklury 200 mg once daily for 1 day followed by Veklury 100 mg once daily for 2 days (for a total of 3 days of

intravenously administered therapy) in 562 adult and paediatric patients (12 years of age and older and weighing at least 40 kg) with confirmed SARS-CoV-2 infection and at least one risk factor for progression to hospitalisation. Risk factors for disease progression were: aged  $\geq 60$  years, chronic lung disease, hypertension, cardiovascular or cerebrovascular disease, diabetes mellitus, obesity, immunocompromised state, chronic mild or moderate kidney disease, chronic liver disease, current cancer, or sickle cell disease. Vaccinated patients were excluded from the study. The baseline serostatus of the patients was unknown.

Patients were randomized in a 1:1 manner, stratified by residence in a skilled nursing facility (yes/no), age ( $< 60$  vs  $\geq 60$  years), and region (US vs ex-US) to receive Veklury (n=279) or placebo (n=283), plus standard of care.

At baseline, mean age was 50 years (with 30% of patients aged 60 or older); 52% were male, 80% were White, 8% were Black, 2% were Asian, 44% were Hispanic or Latino; median body mass index was 30.7 kg/m<sup>2</sup>. The most common comorbidities were diabetes mellitus (62%), obesity (56%), and hypertension (48%). Median (Q1, Q3) duration of symptoms prior to treatment was 5 (3, 6) days; median viral load was 6.3 log<sub>10</sub> copies/ml at baseline. The baseline demographics and disease characteristics were well balanced across the Veklury and placebo treatment groups.

The primary endpoint was the proportion of patients with COVID-19 related hospitalisation (defined as at least 24 hours of acute care) or all-cause 28-day mortality. Events (COVID-19-related hospitalisation or all-cause 28-day mortality) occurred in 2 (0.7%) patients treated with Veklury compared to 15 (5.3%) patients concurrently randomized to placebo, demonstrating an 87% reduction in COVID-19-related hospitalisation or all-cause mortality compared to placebo (hazard ratio, 0.134 [95% CI, 0.031 to 0.586]; p=0.0076). No deaths were observed at Day 28.

### *QT*

Current non-clinical and clinical data do not suggest a risk of QT prolongation, but QT prolongation has not been fully evaluated in humans.

### *Temporary authorisation*

The medicinal product Veklury has been granted temporary authorisation as the clinical data was incomplete at the time the authorisation application was assessed (Art. 9a TPA). The temporary authorisation is contingent on the timely fulfilment of conditions. After they have been met, the temporary authorisation can be transformed into an ordinary authorisation.

### Pharmacokinetics

The pharmacokinetic properties of remdesivir have been investigated in healthy volunteers. No pharmacokinetic data is available from patients with COVID-19.

#### *Absorption*

The pharmacokinetic properties of remdesivir and the predominant circulating metabolite GS-441524 have been evaluated in healthy adult subjects. Following intravenous administration of Veklury adult dosage regimen, peak plasma concentration was observed at end of infusion, regardless of dose level, and declined rapidly thereafter with a half-life of approximately 1 hour. Peak plasma concentrations of GS-441524 were observed at 1.5 to 2.0 hours post start of a 30 minute infusion.

#### *Distribution*

Remdesivir is approximately 88 to 93% bound to human plasma proteins (ex-vivo data). The binding is independent of drug concentration over the range of 1 to 10  $\mu\text{M}$ , with no evidence for saturation of remdesivir binding. Protein binding of GS-441524 was low (2% bound) in human plasma. After a single 150 mg dose of [ $^{14}\text{C}$ ]-remdesivir in healthy subjects, the blood to plasma ratio of  $^{14}\text{C}$ -radioactivity was approximately 0.68 at 15 minutes from start of infusion, increased over time reaching ratio of 1.0 at 5 hours, indicating differential distribution of remdesivir and its metabolites to plasma or cellular components of blood.

#### *Metabolism*

Remdesivir is extensively metabolised to the pharmacologically active nucleoside analog triphosphate GS-443902 (formed intracellularly). The metabolic activation pathway involves initial hydrolysis to an intermediate metabolite, GS-704277. This reaction is catalyzed primarily (80%) by CES1 enzymes, with minor contributions from cathepsin A and CYP3A (approximately 10% each). Phosphoramidate cleavage of GS-704277, catalyzed by the enzyme HINT1, is then followed by successive phosphorylation to form the active triphosphate, GS-443902. Dephosphorylation of all phosphorylated metabolites can result in the formation of nucleoside metabolite GS-441524 that itself is not efficiently re-phosphorylated. The human mass balance study also indicates presence of a currently unidentified major metabolite (M27) in plasma.

#### *Elimination*

Following a single 150 mg intravenous dose of [ $^{14}\text{C}$ ]-remdesivir, mean total recovery of the dose was 92%, consisting of approximately 74% and 18% recovered in urine and feces, respectively. The majority of the remdesivir dose recovered in urine was GS-441524 (49%), while 10% was recovered as remdesivir. These data indicate that renal clearance is the major elimination pathway for GS-441524. The median terminal half-lives of remdesivir and GS-441524 were approximately 1 and 27 hours, respectively.

### *Kinetics in specific patient groups*

#### *Age, gender and ethnicity*

Pharmacokinetic differences for gender, race, and age have not been evaluated.

#### *Hepatic impairment*

The pharmacokinetics of remdesivir and GS-441524 in hepatic impairment have not been evaluated. The role of the liver in the metabolism of remdesivir is unknown.

#### *Renal impairment*

The pharmacokinetics of remdesivir and GS-441524 in renal impairment have not been evaluated. Remdesivir is not cleared unchanged in urine to any substantial extent, but its main metabolite GS-441524 is renally cleared and the metabolite levels in plasma may theoretically increase in patients with impaired renal function. The excipient betadex sulfobutyl ether sodium is renally cleared and accumulates in patients with decreased renal function. Veklury should not be used in patients with eGFR < 30 ml/min.

#### *Paediatric patients*

The pharmacokinetics in paediatric patients have not been evaluated.

### **Preclinical data**

#### *Toxicology*

Following intravenous administration (slow bolus) of remdesivir to rhesus monkeys and rats, severe renal toxicity occurred after short treatment durations. In male rhesus monkeys at dosage levels of 5, 10, and 20 mg/kg/day for 7 days resulted, at all dose levels, in increased mean urea nitrogen and increased mean creatinine, renal tubular atrophy, and basophilia and casts, and an unscheduled death of one animal at the 20 mg/kg/day dose level. In rats at dosage levels of > 3 mg/kg/day for up to 4 weeks resulted in findings indicative of kidney injury and/or dysfunction. Systemic exposures (AUC) of the predominant circulating metabolite of remdesivir (GS-441524) were 0.1 times (monkeys at 5 mg/kg/day) and 0.3 times (rat at 3 mg/kg/day) the exposure in humans following intravenous administration at the recommended human dose (RHD). An unidentified major metabolite (M27) was shown to be present in human plasma (see "Pharmacokinetics"). The exposure of M27 in rhesus monkeys and rats is unknown. Animal studies may therefore not be informative of potential risks associated with this metabolite.

#### *Mutagenicity*

Remdesivir was not genotoxic in a battery of assays, including bacterial mutagenicity, chromosome aberration using human peripheral blood lymphocytes, and *in vivo* rat micronucleus assays.

### *Carcinogenicity*

Long-term animal studies to evaluate the carcinogenic potential of remdesivir have not been performed.

### *Reproductive toxicity*

In female rats, decreases in corpora lutea, numbers of implantation sites, and viable embryos were seen when remdesivir was administered intravenously daily at a systemically toxic dose (10 mg/kg/day) 14 days prior to mating and during conception; exposures of the predominant circulating metabolite (GS-441524) were 1.3 times the exposure in humans at the RHD. There were no effects on female reproductive performance (mating, fertility, and conception) at this dose level.

In rats and rabbits, remdesivir demonstrated no adverse effect on embryofoetal development when administered to pregnant animals at systemic exposures (AUC) of the predominant circulating metabolite of remdesivir (GS-441524) that were up to 4 times the exposure in humans at the RHD. In animal studies, the nucleoside analog metabolite GS-441524 has been detected in the blood of nursing rat pups of mothers given remdesivir. Therefore, excretion of remdesivir and/or metabolites into the milk of lactating animals can be assumed.

In rats, there were no adverse effects on pre- and post-natal development at systemic exposures (AUC) of the predominant circulating metabolite of remdesivir (GS-441524) that were similar to the exposure in humans at the RHD.

It is unknown if the active nucleoside analog triphosphate GS-443902 and the unidentified major human metabolite M27 are formed in rats and rabbits. The reproductive toxicity studies may therefore not be informative of potential risks associated with these metabolites.

### **Other information**

#### *Incompatibilities*

This medicinal product must not be mixed or administered with simultaneously other medicinal products in the same dedicated line except those mentioned in section "Instructions for handling".

#### *Shelf life*

Do not use this medicinal product after the expiry date ("EXP") stated on the container.

#### *Shelf life after opening*

#### *Reconstituted and diluted solution for infusion*

Store diluted Veklury solution for infusion up to 4 hours at below 25°C or 24 hours in a refrigerator (2°C to 8°C).



### *Special precautions for storage*

Keep out of reach of children.

Do not store above 30°C.

For storage conditions after reconstitution and dilution of the medicinal product, see “Shelf life”.

### *Instructions for handling*

Prepare solution for infusion under aseptic conditions and on the same day as administration. Veklury should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Should either be observed, the solution should be discarded and fresh solution prepared.

Veklury must be reconstituted with 19 ml sterile water for injections and diluted in sodium chloride 9 mg/ml (0.9%) solution for injection before being administered via intravenous infusion over 30 to 120 minutes.

### *Preparation of Veklury solution for infusion*

#### *Reconstitution*

Remove the required number of single-use vial(s) from storage. For each vial:

- Aseptically reconstitute remdesivir powder for concentrate for solution for infusion by addition of 19 ml of sterile water for injections using a suitably sized syringe and needle per vial.
  - Discard the vial if a vacuum does not pull the sterile water for injections into the vial.
- Only use **sterile water** for injection to reconstitute Veklury.
- Immediately shake the vial for 30 seconds.
- Allow the contents of the vial to settle for 2 to 3 minutes. A clear solution should result.
- If the contents of the vial are not completely dissolved, shake the vial again for 30 seconds and allow the contents to settle for 2 to 3 minutes. Repeat this procedure as necessary until the contents of the vial are completely dissolved.
- Inspect the vial to ensure the container closure is free from defects and the solution is free of particulate matter.
- Dilute immediately after reconstitution.

#### *Dilution*

Care should be taken to prevent inadvertent microbial contamination. As there is no preservative or bacteriostatic agent present in this product, aseptic technique must be used in preparation of the final parenteral solution. It is always recommended to administer IV medicines immediately after preparation when possible.

- Using Table 4, determine the volume of sodium chloride 9 mg/ml (0.9%) solution for injection to withdraw from the infusion bag.



**Table 4: Recommended dilution instructions - Reconstituted Veklury powder for concentrate for solution for infusion**

<b>Veklury dose</b>	<b>Sodium chloride 9 mg/ml (0.9%) infusion bag volume to be used</b>	<b>Volume to be withdrawn and discarded from sodium chloride 9 mg/ml (0.9%) infusion bag</b>	<b>Required volume of reconstituted Veklury</b>
200 mg (2 vials)	250 ml	40 ml	2 x 20 ml
	100 ml	40 ml	2 x 20 ml
100 mg (1 vial)	250 ml	20 ml	20 ml
	100 ml	20 ml	20 ml

NOTE: 100 ml should be reserved for patients with severe fluid restriction, e.g. with ARDS or renal failure.

- Withdraw and discard the required volume of sodium chloride 9 mg/ml from the bag using an appropriately sized syringe and needle per Table 4.
- Withdraw the required volume of reconstituted remdesivir powder for concentrate for solution for infusion using an appropriately sized syringe per Table 4. Discard any unused portion remaining in the remdesivir vial.
- Transfer the required volume of reconstituted remdesivir powder for concentrate for solution for infusion to the selected infusion bag.
- Gently invert the bag 20 times to mix the solution in the bag. Do not shake.
- The prepared solution is stable for 4 hours at room temperature (20°C to 25°C) or 24 hours in the refrigerator (at 2°C to 8°C) (including any time before dilution into intravenous infusion fluids).

After infusion is complete, flush with at least 30 ml of sodium chloride 9 mg/ml.

#### *Disposal*

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

#### **Authorisation number**

68026 (Swissmedic)

#### **Packs**

Veklury 100 mg powder for concentrate for solution for infusion: 1 vial [A]

#### **Marketing authorisation holder**

Gilead Sciences Switzerland Sàrl, Zug

#### **Date of revision of the text**

June 2022